|
|
 |
|
Viewing report
|
|
|
|
Drugs of Tomorrow: Antipsychotics - Gaining Competitive Advantage From a Limited Research Base
Datamonitor, Aug 2002
The antipsychotics market is entering a new era. Currently, the market is going through a period of rapid commercial expansion due to the success of the atypical mixed neuroreceptors such as Zyprexa (olanzapine) and Risperdal (risperidone). However, a new wave of antipsychotics are progressing though the pipeline that focus on drug delivery and pharmacokinetics. This analysis examines the current unmet needs of the market and predicts how developmental compounds will target these needs.Key data and market dynamics across the seven leading markets: the US, Japan, Germany, France, Italy, Spain, and the UKReview of innovative early phase antipsychotic products and the entry strategies to satisfy market needsDetailed analysis of the antipsychotic pipeline and R&D strategy of numerous companies including Sanofi-Synthélabo, Novartis, Janssen and Lundbeck.Critique of antipsychotic trial design and strategies to decease placebo responseNovartis’ Zomaril (iloperidone) has received much negative publicity due to its association QTc interval increase. In addition, clinical trials have shown it light on efficacy. However, a monthly IM depot will differentiate it from the market, and Novartis’ vast experience of marketing Clozaril is expected to see Zomaril fight back to gain respectable revenues.BMS’ Abilitat (aripiprazole) has an impressive clinical profile, and Datamonitor expects the drug enter the algorithm behind Zyprexa-pressuring Risperdal revenues. However, due to the lack of a sedative effect and IM depot formulation, the drug is not expected to be targeted at the acute schizophrenia market.Optimize your knowledge of company strategies in the antipsychotic marketEnhance your sales forecasting ability and future product positioning through identification of market driversIncrease your competitive intelligence by accessing drug profiles and forecast product performance to 2010Optimize your understanding of the unmet needs in the market and mechanisms to satisfy these needs
Customers who bought this item also bought
Drugs of Tomorrow 2001: Antipsychotics - New Players in an Expanding Market
Pipeline Insight: Antipsychotics - Novel Antipsychotics Driving Market Evolution
Drugs of Tomorrow: Alzheimer’s Disease - Ebixa Set to Expand Billion Dollar Market
Market Dynamics: Antipsychotics - A Market Driven by Reformulation
Drugs of Tomorrow 2001: Stable Angina - An Unsatisfactory R&D Pipeline Facing Chronic Unmet Needs
Drugs of Tomorrow 2002: Depression - A pipeline driven by side effect profile
Drugs of Tommorrow 2002: Pain
The World Market for Butadiene Rubber (BR): A 2009 Global Trade Perspective
The 2009 Import and Export Market for Butadiene Rubber (BR) in Iran
The 2009 Import and Export Market for Butadiene Rubber (BR) in Belarus
The 2009 Import and Export Market for Butadiene Rubber (BR) in Bulgaria
The 2009 Import and Export Market for Butadiene Rubber (BR) in Colombia
|
|
|
|
